

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Bayer (diabetic kidney disease); Idorsia (phase 3 RHTN); Novartis (RHTN; cognitive function/chronic HFpEF); ROX Med (multicenter study); Vascular Dynamics (PMA-RHTN)	Research/Research Grants ‡ Bayer (Site PI-diabetic kidney disease); Novartis (site PI-resistant HTN; site PI-cognitive function/chronic HFpEF)	Significant (>= \$5,000)	Acute Coronary Syndromes Prevention Vascular Medicine Other
CinCor Pharma Inc	Research/Research Grants ‡ Studies on evaluation of safety (CIN-107-121, CIN-107-122) for treatment of patients with primary aldosteronism/treatment resistant hypertension	Significant (>= \$5,000)	Other
Idorsia (Aprocintan Advisory Board); ROX Medical (ROX Control HTN 2 Study US Steering Committee 07/2017-present)	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology Prevention Vascular Medicine Other
Preventric Diagnostics, Inc	Other - Chief Medical Officer; Independent contractor (CMO) development of hypertension and pulmonary health platform (BP monitoring)	Modest (< \$5,000)	Prevention
Springer (Current Hypertension Reports)	Other - Editor-in-Chief, Current Hypertension Reports (Journal; Publisher – Springer Science Business Media LLC	Modest (< \$5,000)	General Cardiology Vascular Medicine Other

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Current Hypertension Reports (Journal; Publisher-Springer Science Business Media LLC) ‡ Publisher-Springer Science Business Media LLC (annual stipend of \$5,000)	Other - Editor-in-Chief	Modest (< \$5,000)	General Cardiology
National Institutes of Health ‡ Director/PI UAB Clinical Center Network NIH/NHLBI-funded Systolic Blood Pressure Intervention Trial; and sub-investigator UAB clinical site (PI: Calhoun)	Research/Research Grants ‡ Systolic Blood Pressure Intervention Trial (SPRINT)	Significant (>= \$5,000)	Other
World Heart Federation (WHF), European Society of Hypertension (ESH), European Public Health Association (EPH) ‡ Global Working Group-Optimal Salt Consumption and CV Health, Writing Group- White Paper on Salt and CVD (WHF/ESH/EPH)	Other - Work Group/Writing Group Member	Modest (< \$5,000)	General Cardiology

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/14/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/14/2022

Embargo | Signed on 6/14/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 6/14/2022

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.